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Abstract
Introduction: Accurate clinical laboratory reference values derived from a local or regional population base are required to
correctly interpret laboratory results. In Botswana, most reference intervals used to date are not standardized across clinical
laboratories and are based on values derived from populations in the United States or Western Europe.
Methods: We measured 14 hematologic and biochemical parameters of healthy young adults screened for participation in
the Botswana HIV Pre-exposure Prophylaxis Study using tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) (TDF2
Study). Reference intervals were calculated using standard methods, stratified by gender, and compared with the site-
derived reference values used for the TDF2 study (BOTUSA ranges), the Division of AIDS (DAIDS) Grading Table for Adverse
Events, the Botswana public health laboratories, and other regional references.
Results: Out of 2533 screened participants, 1786 met eligibility criteria for participation in study and were included in the
analysis. Our reference values were comparable to those of the Botswana public health system except for amylase, blood
urea nitrogen (BUN), phosphate, total and direct bilirubin. Compared to our reference values, BOTUSA reference ranges
would have classified participants as out of range for some analytes, with amylase (50.8%) and creatinine (32.0%) producing
the highest out of range values. Applying the DAIDS toxicity grading system to the values would have resulted in 45 and 18
participants as having severe or life threatening values for amylase and hemoglobin, respectively.
Conclusion: Our reference values illustrate the differences in hematological and biochemical analyte ranges between
African and Western populations. Thus, the use of western-derived reference laboratory values to screen a group of
Batswana adults resulted in many healthy people being classified as having out-of-range blood analytes. The need to
establish accurate local or regional reference values is apparent and we hope our results can be used to that end in
Botswana.
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Introduction
Clinical laboratory testing is the most widely used medical
decision-making tool [1] and is crucial for disease screening,
diagnosis, monitoring disease progression and treatment efficacy.
Correct interpretation of laboratory tests requires accurate
reference intervals from an appropriate population [2]. Reference
intervals are typically established by assaying specimens from a
sample group of people who meet carefully defined criteria [3].
The reference interval is usually defined as the values encompass-
ing the central 95% of specimens; equating to 2 standard
deviations on either side of the mean [4]. Producing reference
intervals for a general population is a major challenge, as it
requires selecting the appropriate reference population and
recruiting individuals who represent relevant demographic groups
that meet the inclusion criteria; collecting, processing and testing
specimens; and finally, calculating reference values with possible
stratification of the data into subgroups.
The currently used reference values in Botswana vary by
individual clinical laboratory. For example, some laboratories use
values supplied in a manufacturer’s kit insert but those values are
derived from populations outside the country and may not
accurately represent normal values for the Botswana population.
Without Botswana-based reference values, there could be consid-
erable misclassification of normal and abnormal test results. This is
especially important when implementing lifesaving anti-retroviral
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(ARV) drug therapy for HIV infected persons. ARVs can have
adverse effects which must be recognized early on using
appropriate laboratory reference values. As the number of HIV
prevention and treatment clinical trials in Botswana has increased
greatly, accurate reference values are needed to correctly screen
volunteers for study eligibility and as well as monitoring for
possible adverse events. A few studies reporting immuno-
hematological reference values for the Botswana population exist
[5,6] but there is little, if any, local reference information available
for clinical biochemistry parameters in Batswana adults.
Our manuscript reports several hematologic and chemistry
parameters among a group of healthy Batswana adults. We used
those results to create reference intervals and compared our
reference intervals to those already in use in Botswana and in
neighboring countries.
Methods
The Botswana TDF2 HIV Pre-Exposure Prophylaxis Study
(the TDF2 Study)
The laboratory values reported here are from volunteers
screened for the TDF2 Study [7]. In brief, this study determined
the safety and efficacy of daily oral dosing of the combination
antiretroviral drug TDF/FTC (tenofovir disoproxil fumarate/
emtricitabine) for the prevention of HIV infection in heterosex-
ually active young adults in Botswana. The study was conducted
between March 2007 and May 2010 in the Botswana cities of
Gaborone and Francistown. The study enrolled 1219 participants
from a total screened population of 2533 sexually active
participants aged between 18 and 39 years (median age 24) and
randomized them 1:1 to once daily TDF/FTC or to placebo.
Pregnant or breastfeeding participants were excluded from the
study and participants who were found to be out of range while
screening for the TDF2 were referred to local health settings for
assistance while those found to be abnormal after enrollment were
taken off study medication prior to being referred to local health
settings.
This study is registered with clinicaltrial.gov number
NCT00448669.
Ethical Approval
The study protocol was approved by the CDC Institutional
Review Board and the Botswana Health Research Development
Committee. Each participant provided written informed consent
prior to study screening and enrollment. Parental or guardian
assent was also obtained for participants 18–20 years of age
considered to be minors as per the Botswana legal system.
Reference Range Analysis
Of the 1859 TDF2 study participants who underwent chemistry
and hematology testing, 73 were excluded from analysis due to
factors that rendered them ineligible for study participation and
could have affected their suitability for reference values. Of the 73
excluded, 64 (87.7%) were positive for HBsAg, 7 (9.6%) were
HIV-positive, 1 (1.4%) was on medication for chronic illness and 1
(1.4%) was breastfeeding. This left a total sample of 1786
participants from whom the reference ranges were calculated
(Figure 1). The chemistry and hematology tests performed
included hemoglobin (Hb) and hematocrit (Hct), creatinine,
inorganic phosphorus, bicarbonate (HCO3), potassium, sodium,
chloride, blood urea nitrogen (BUN), direct and total bilirubin,
serum amylase, aspartate amino transferase (AST) and alanine
aminotransferase (ALT).
The TDF2 study used two reference range tables to classify
laboratory abnormalities: the BOTUSA site derived reference
ranges (Table 1 column 3) were used to classify results as normal or
abnormal and together with the study exclusion/inclusion criteria
used to decide on study participation of a client. Grading values
derived from the 2004 Division of AIDS (DAIDS) grading system
(Table 1 columns 5–8) were used for grading adverse events during
the trial. The BOTUSA site-derived reference ranges were
extracted from what the Botswana public health laboratories used
at the inception of the TDF2 study and derived from western
populations according to the methodologies existent then. Both the
DAIDS and the TDF2 study reference ranges were derived from
western populations.
Blood Collection and Testing Methodologies
Blood specimens were collected in the clinics at each study site
and transported in coolers from the on-site clinic laboratories to
the off-site laboratories which were a 5 to10 minute drive away.
For hematology, the blood was collected in a Becton Dickinson
(BD) ethylene diamine tetra-acetic acid (EDTA) Vacutainer tube
(Franklin Lakes, NJ, USA), while that for biochemistry was
collected in a BD serum separation tube (SST) that was
centrifuged (3,0006 g, 3 minutes) within two hours of sample
collection.
Prior to use, both chemistry and hematology instruments ware
validated on site using validation panels from Contract Laboratory
Services (CLS) South Africa. A Sysmex XT1800i hematology
analyzer (Symex, Kobe, Japan) was used for hemoglobin and
hematocrit within 24 hours of whole blood sample collection as
recommended by the manufacturer and a Roche Integra 400plus
analyzer was used for chemistry tests. To maintain internal quality
control, the equipment had to satisfy the calibration criteria prior
to analysis, only reagents within expiration dates were used, and a
second laboratory technologist had to validate the results of the
first reader and authorize them for release. Testing staff were
Good Clinical Laboratory Practices (GCLP) certified and had to
be audited against the GCLP standards quarterly. For hematology
testing each day, at least two levels of e-check controls (levels 1, 2,
or 3) were run and both results had to be within range before
testing patient samples; for chemistry tests, control results for two
level of controls s (pathological/abnormal and non-pathological/
normal) had to be shown to be within acceptable ranges before
testing participants’ samples. Proficiency testing panels were
performed three times a year and evaluated by the College of
American Pathologists as the external quality control.
Statistical Analysis
The Clinical Laboratory Standards Institute (CLSI) [8]
recommends a sample size of at least 120 values for non-
parametric reference intervals and for parameters not influenced
by gender (60 females and 60 males). For parameters that are
influenced by gender, the minimum recommended number is 240
reference individuals (120 females and 120 males). Hence, our
study sample size (1786; 770 females and 1016 males) exceeded
the recommended CLSI (formerly NCCLS) guideline.
Reference values were estimated using non-parametric meth-
ods. The mean (with 95% confidence interval), median, range, and
2.5 and 97.5 percentiles were computed for each analyte for the
total sample and by gender. Means and the corresponding 95% CI
were computed using bootstrapping. We created 1,000 datasets by
randomly selecting the participants, with replacement, and then
summarizing to obtain the mean and 95% CI. A non-parametric
Wilcoxon rank-sum test was performed to test for gender
differences for each analyte. The reference interval, according to
Hematologic and Biochemistry Reference Intervals
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CLSI, is defined as the interval between and including the upper
and lower reference limits, which are estimated to enclose a
specified percentage (here 95%) of the values for a population from
which the reference subjects were drawn. Our calculated analyte
values were compared to the DAIDS reference intervals. The
overall percentage outside the specified interval, as well as the
percentage of analyte values in each of the severity grades (1–4),
was computed. Lastly, our calculated analyte reference intervals
were compared to those of other African countries.
Results
Characteristics of Study Population
Of the 1786 screened participants, 1016 (56.9%) were males
while 770 (43.1%) were females. 41 of the 1786 participants (2.3%)
were 18–20 years old; 1618 (90.6%) were 21–29 years old; and 127
(7.1%) were 30–39 years old. The median age was 24 years (IQR,
4years). There were. About half of the participants were from each
site [Gaborone (877; 49.1%) and Francistown (909; 50.9%)] and
1045 (58. 5%) reported alcohol use within the prior three months.
Figure 1. The TDF2 Botswana PrEp lab reference values Consort diagram.
doi:10.1371/journal.pone.0093034.g001
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Hematological and Biochemistry Parameters
The analysis results are presented in Table 2. We observed
statistically significant differences in hemoglobin and hematocrit
by gender, with males having higher values than females.
Similarly, males had significantly higher values than females for
most biochemistry parameters, including CO2, potassium, AST,
ALT, creatinine, blood urea nitrogen, total bilirubin, direct
bilirubin and amylase. However, females had significantly higher
values than males for chloride and phosphate parameters.
Using the western-derived BOTUSA reference intervals results,
over 50% of our healthy volunteers were out-of-range for amylase
(Table 1) and over 10% were out of range for ALT, creatinine,
BUN, and hemoglobin (for females). Using DAIDS grading
system, established using the BOTUSA site reference values
40.3% of our participants had abnormal amylase levels and at least
45 participants would have had a severe or life threatening (Grade
3) amylase abnormality (Table 2). Furthermore, 18 and 26
participants would have been classified as having severe or life
threatening hemoglobin and inorganic phosphate levels, respec-
tively.
We found noticeable differences between the newly established
reference intervals by this study and those used in other settings.
Compared to other intervals currently in use in Botswana, our
reference intervals had higher upper limits for ALT, BUN,
bilirubin (total), bilirubin (direct) amylase and phosphate, de-
pressed lower limits for ALT, creatinine, BUN, hemoglobin and
hematocrit (women only), but comparable levels for chloride,
potassium, sodium and hematocrit (men only) (Table 3). Com-
pared to regional-derived values from the Combined Eastern and
Southern Africa and Combined Uganda, Kenya and Zambia
reports, we had lower AST, ALT, creatinine, total and direct
bilirubin values yet higher upper limit intervals for AST and ALT
compared to those from the US Massachusetts General Hospital
(Table 3). The upper limit of our amylase interval was comparable
to that from the US Massachusetts General Hospital (MGH) but
significantly higher than that from the Combined Eastern and
Southern Africa report (Table 3). The hematological values were
comparable to the combined regional intervals and the MGH
values, particularly in males. For females, our lower limit fell
outside the MGH intervals and those currently in use in Botswana.
Discussion
There is paucity of reference interval data in Botswana with
only a few studies conducted on hematological/immunohemato-
logical ranges and one on lipids [5–6,9] for the biochemical
ranges. Reference intervals for laboratory parameters provide
important data for assessment of the health status of an individual.
For this reason reference intervals are routinely used in clinical
trials at enrollment to determine eligibility, establish baseline
measures, and to monitor participants’ health during the course of
the trial. Moreover, analytes including hemoglobin, bilirubin and
neutrophils are used as markers for the presence of disease.
Without locally derived reference values for African populations,
clinicians and researchers often must use reference values obtained
from European or North American populations. However, several
African studies have highlighted differences between locally
derived values and western derived values. Hence, over the last
decade, there has been an increase in the number of studies aimed
at establishing locally derived reference intervals for more effective
patient management and proper conduct of clinical research in
these settings. The use of population based ranges for the TDF
study (Table 1) to assess laboratory data, would have led to a
reduction in out of range clinical trial volunteers for Amylase,
BUN, ALT hemoglobin, inorganic phosphate which could have
translated to rapid enrollment of participants and a savings on
Table 1. The comparison of calculated population biochemical reference values for participants screened (N = 1786; Females = 770
and Males = 1016) for the TDF2 Botswana study with DAIDS and BOTUSA site established ranges.
Analyte Units Comparison (out of range) Division of AIDS Toxicity Grading (DAIDS)
BOTUSA Reference
Interval TDF2 Grade 1 Grade 2 Grade 3 Grade 4
N (%) N (%) N (%) N (%) N (%)
AST (SGOT) IU/L 10–36 71 (3.98) 29 (1.62) 5 (0.28) 1 (0.06) 0 (0.00)
ALT (SGPT) IU/L 11–41 401 (22.45) 33 (1.85) 2 (0.11) 0 (0.00) 0 (0.00)
Creatinine mg/dL 0.7–1.4 572 (32.03) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Blood Urea Nitrogen mg/dL 7.0–30.0 232 (12.99) 1 (0.06) 0 (0.00) 0 (0.00) 0 (0.00)
Bilirubin (Total) mg/dL 0.1–1.3 110 (6.16) 82 (4.59) 26 (1.46) 2 (0.11) 0 (0.00)
Bilirubin (Direct) mg/dL 0.1–0.4 69 (3.86) 25 (1.40) 16 (0.90) 0 (0.00) 0 (0.00)
Amylase IU/L 60–97 908 (50.84) 492 (27.55) 182 (10.19) 44 (2.46) 1(0.06)
Phosphate (inorganic) mg/dL 2.5–4.5 150 (8.40) 39 (2.18) 106 (5.94) 26 (1.46) 0 (0.00)
Chloride mEq/L 95–108 14 (0.78) 14 (0.78) 0 (0.00) 0 (0.00) 0 (0.00)
CO2 mEq/L 21–29 146 (8.17) 94 (5.26) 0 (0.00) 1 (0.06) 0 (0.00)
Potassium (Indirect) mEq/L 3.5–5.1 70 (3.92) 26 (1.46) 1 (0.06) 0 (0.00) 0 (0.00)
Sodium (Indirect) mEq/L 135–145 24 (1.34) 22 (1.23) 1 (0.06) 1 (0.06) 0 (0.00)
Hemoglobin Males g/dl 13–17 110 (6.16) 35 (1.96) 15 (0.84) 16 (0.90) 2 (0.11)
Hemoglobin Females g/dl 12–15 193 (10.81)
Hematocrit Males % 40–50 125 (7.00) - - - -
Hematocrit Females % 36–45 147 (8.23)
doi:10.1371/journal.pone.0093034.t001
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Table 2. The calculated population biochemical reference values for participants screened (N = 1786; Females = 770 and






Aspartate Aminotransferase Combined 21.55 (21.09, 22.04) 20.0 10.0–204.0 13.0–42.0 ,0.001
(AST/SGOT) Female 18.57 (18.13, 19.14) 17.0 10.0–134.0 12.0–31.0
IU/L Male 23.80 (23.12, 24.61) 22.0 11.0–204.0 14.0–48.0
Alanine Aminotransferase Combined 17.48 (16.96, 18.02) 15.0 0.0–152.0 7.0–46.0 ,0.001
(ALT/SGPT) Female 14.25 (13.64, 14.87) 12.0 0.0–148.0 7.0–33.0
IU/L Male 19.94 (19.20, 20.68) 17.0 3.0–152.0 8.0–53.0
Creatinine Combined 0.74 (0.73, 0.74) 0.7 0.3–1.4 0.5–1.1 ,0.001
mg/dL Female 0.62 (0.61, 0.62) 0.6 0.3–1.1 0.5–0.8
Male 0.83 (0.82, 0.83) 0.8 0.5–1.4 0.6–1.1
Blood Urea Nitrogen Combined 10.19 (10.00, 10.38) 9.0 3.0–75.0 5.0–21.0 ,0.001
mg/dL Female 9.72 (9.43, 10.00) 9.0 3.0–37.0 5.0–21.0
Male 10.54 (10.28, 10.82) 10.0 4.0–75.0 5.0–22.0
Bilirubin (Total) Combined 0.66 (0.64, 0.68) 0.5 0.1–3.6 0.2–1.8 ,0.001
mg/dL Female 0.51 (0.48, 0.53) 0.4 0.1–3.0 0.2–1.3
Male 0.78 (0.75, 0.81) 0.7 0.2–3.6 0.3–2.1
Bilirubin (Direct) Combined 0.18 (0.17, 0.18) 0.2 0.0–0.8 0.1–0.4 ,0.001
mg/dL Female 0.14 (0.14, 0.15) 0.1 0.0–0.8 0.0–0.3
Male 0.21 (0.20, 0.21) 0.2 0.0–0.8 0.1–0.5
Amylase Combined 96.11 (94.59, 97.82) 91.0 27.0–473.0 47.0–176.0 ,0.001
IU/L Female 90.99 (88.91, 93.38) 87.0 32.0–417.0 46.0–162.0
Male 99.99 (97.61, 102.35) 94.0 27.0–473.0 49.0–181.0
Phosphate (Inorganic) Combined 3.27 (3.24, 3.29) 3.3 1.3–5.2 2.2–4.3 ,0.001
mg/dL Female 3.37 (3.34, 3.41) 3.4 1.8–5.0 2.3–4.4
Male 3.18 (3.15, 3.22) 3.2 1.3–5.2 2.0–4.3
Chloride Combined 102.61 (102.50, 102.72) 103.0 95.0–112.0 98.0–107.0 ,0.001
mEq/L Female 103.63 (103.49, 103.79) 103.0 95.0–112.0 100.0–108.0
Male 101.84 (101.70, 101.97) 102.0 96.0–112.0 98.0–106.0
CO2 Combined 24.71 (24.60, 24.82) 24.7 10.0–32.8 19.9–29.1 ,0.001
mEq/L Female 23.57 (23.43, 23.71) 23.5 16.9–30.4 19.2–27.7
Male 25.58 (25.45, 25.71) 25.6 10.0–32.8 21.3–29.5
Potassium (Indirect) Combined 4.32 (4.30, 4.34) 4.3 2.9–5.8 3.6–5.2 0.006
mEq/L Female 4.28 (4.26, 4.31) 4.3 2.9–5.8 3.6–5.1
Male 4.34 (4.32, 4.37) 4.3 3.1–5.7 3.6–5.2
Sodium (Indirect) Combined 139.08 (138.98, 139.18) 139.0 127.0–156.0 135.0–143.0 ,0.001
mEq/L Female 138.86 (138.72, 139.01) 139.0 132.0–146.0 135.0–143.0
Male 139.24 (139.11, 139.37) 139.0 127.0–156.0 135.0–143.0
Hemoglobin (Hg) Combined 14.46 (14.36, 14.54) 14.7 6.4–24.9 10.4–17.6 ,0.001
g/dL Female 12.87 (12.76, 12.97) 13.0 6.4–16.6 9.1–15.3
Male 15.66 (15.59, 15.74) 15.6 9.4–24.9 13.2–17.8
Hematocrit (Hct) Combined 43.13 (42.90, 43.33) 43.5 23.8–68.0 32.9–51.7 ,0.001
% Female 39.17 (38.90, 39.41) 39.4 23.8–50.2 30.6–45.6
Male 46.12 (45.93, 46.31) 46.0 35.0–68.0 40.2–52.9
Note:
*P-value is for the Wilcoxon rank-sum test for Females versus Males.
doi:10.1371/journal.pone.0093034.t002
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resources utilized for attending to adverse events. Using popula-
tion based reference ranges to work out toxicity tables for the study
would also have resulted in fewer participants classified as grades
1–4 and requiring management and intensified monitoring.
Similar to other African studies, a substantial number of our
TDF2 participants would have been excluded from participating
in a clinical trial if the instrument/assay kit-derived values
currently in use in most hospitals were applied (Table 3). A study
in Uganda reported up to 31% exclusion using western-derived
intervals for recruitment into a clinical trial while only 17% of
these participants would have been excluded if they had used
locally established reference intervals [10]. Similarly, a Kenya
study reported up to a 40% exclusion rate if western-derived
values were applied compared to population based reference
intervals for a rural population [11]. These misclassifications have
a negative impact by wasting scarce resources and creating time
delays in clinical trials and more importantly in creating
misdiagnoses. Therefore, the need to have accurate, locally-
derived reference intervals is a fundamental requisite for
establishing adequate medical care and conducting more efficient-
ly run clinical trials for the benefit of African populations.
Significant gender differences for hemoglobin and hematocrit
levels in our study are consistent with previous reports of higher
Hb and Hct levels in males than females and can be explained by
the likely effect of androgens on erythropoiesis that increases the
number of circulating RBC’s with a resultant hemodilution [11–
15]. The lower Hb levels in women are a common phenomenon in
several other African studies [10–12,15–19] these levels can
further be exacerbated by poor nutritional status resulting in iron
deficiency, genetic disorders including thalassemia and sickle cell
trait or infections with helminthes, malaria or schistosomiasis for
which we did not test. Our findings that males have higher levels
of CO2, potassium, AST, ALT, creatinine, blood urea nitrogen,
bilirubin (total and direct), and amylase, and lower levels of
chloride and phosphate (inorganic) is consistent with previous
studies [10–11,15]. Even though we observed significant differ-
ences in a majority of parameters, these may not be of medical
significance and warrants further investigation.
Several limitations could be cited for our study. Though the
study population was from the cities of Francistown and Gaborone
with representative populations from most of the areas of
Botswana, the ranges established cannot be generalized to the
whole of Botswana. Information on other factors that could
possibly affect analyte levels such as diet, lifestyle were not
collected from the participants. Additionally, although alcohol
may affect several biochemical parameters including Amylase, this
was not investigated in the present study. The inclusion of women
on hormonal contraceptives in this study population means that
hormonal effects on biochemical and hematological analytes could
not be ruled out. While the study used a single platform for
biochemistry and hematology, the CLSI guidelines require that
individual laboratories perform evaluations with limited sample
size to verify the applicability of such references within their
setting. Moreover the platforms used in this study are commonly
used in the Botswana public health setting.
Even with the above limitations, our results were still
comparable with other studies in the region. Our hemoglobin
and hematocrit intervals were comparable to those obtained in a
recent Botswana study, [6] but there were variations that were
likely due to a larger geographic area and a more ethnically
diverse population in our sample. In addition, our intervals came
from a larger sample size and they agreed overall with the recently
published combined Eastern and Southern Africa consensus
intervals, [19] except serum amylase. However, our amylase
intervals were similar to the intervals in a study of health Ugandan
blood donors [10] indicating that these levels are not uncommon
in the African setting. Though the gender differences for some
parameters in our study are statistically significant, the absolute
value of those differences is relatively small. It may be that these
differences are not of sufficient clinical significance to warrant the
establishment of different standards between men and women.
The accumulation of more reference data from other sources will
help to clarify that question.
Given that the frequency of clinical trials and persons receiving
clinical services is increasing substantially in sub-Saharan Africa,
the introduction of geographic and ethnically valid laboratory
intervals is needed for establishing accurate toxicity tables for use
in patient management as well as in recruiting and monitoring
participants in clinical trials in addition to the DAIDS toxicity
grading tables. The established intervals are appropriate for use in
young adult population in Botswana and need to be validated
using a smaller sample size as indicated in the CLSI guidelines [8].
The accuracy of our tables will increase as more data from
representative populations becomes available. As this process of
revising the tables unfolds, it will be important to verify that the
revised intervals do in fact represent healthy norms for Africa. For
that reason, it is important that interventional trials should
continue to carefully review their data to ensure that persons
whose laboratory values fall within the new ranges are indeed at
no greater risk as compared to the current tables. Our reference
intervals, in addition to the existing intervals could be used for
comparison by the Botswana Ministry of health in establishing
Botswana population based reference ranges for standardization of
laboratory diagnosis.
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